PG
SRPT icon

PEAK6 Group’s Sarepta Therapeutics SRPT Stock Holding History

PEAK6 Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$3.69M Sell
27,900
-60,300
-68% -$5.69M 0.02% 948
2018
Q1 		$6.54M Buy
+88,200
New +$5.88M 0.03% 662
2016
Q4 		– Sell
-24,000
Closed -$1.47M – 5072
2016
Q3 		$1.47M Buy
+24,000
New +$726K 0.01% 1486
2016
Q2 		– Sell
-20,800
Closed -$406K – 4735
2016
Q1 		$406K Buy
+20,800
New +$363K ﹤0.01% 2472
2015
Q4 		– Sell
-17,000
Closed -$546K – 5251
2015
Q3 		$546K Buy
+17,000
New +$577K ﹤0.01% 2806
2015
Q1 		– Sell
-24,300
Closed -$352K – 5222
2014
Q4 		$352K Sell
24,300
-3,100
-11% -$52.5K ﹤0.01% 2876
2014
Q3 		$578K Buy
+27,400
New +$618K ﹤0.01% 2355
2013
Q4 		– Sell
-11,800
Closed -$279K – 5414
2013
Q3 		$279K Buy
+11,800
New +$454K ﹤0.01% 3381

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

PEAK6 Group's SRPT Position: Q4 2013 in Review

PEAK6 Group sold out of Sarepta Therapeutics (SRPT) in Q4 2013, closing a stake of 4,000 shares — an estimated $94.1K sold.

PEAK6 Group first reported a position in SRPT in Q3 2013 and held it in 1 quarter. The position peaked at $94.1K in Q3 2013. 108 funds tracked by Wall St. Rank hold SRPT as of Q4 2013.

  • PEAK6 Group reported no remaining Sarepta Therapeutics position as of Q4 2013 after selling out during the quarter.
  • PEAK6 Group sold 4,000 Sarepta Therapeutics shares in Q4 2013, an estimated $94.1K.
  • PEAK6 Group first reported a position in Sarepta Therapeutics in Q3 2013 and held it in 1 quarter.
  • PEAK6 Group's Sarepta Therapeutics position peaked at $94.1K in Q3 2013.
  • 108 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2013.

Based on PEAK6 Group's 13F filing for Q4 2013, filed 13 Feb 2014.